Phys.org September 4, 2024 In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, and an additional outbreak in Central Africa of clade I virus. A team of researchers in the US (United States Army Medical Research Institute of Infectious Diseases, industry, NIH, Boston University) tested mRNA-1769, an mRNA-lipid nanoparticle (LNP) vaccine expressing MPXV surface proteins, in a lethal MPXV primate model. Similar to MVA, mRNA-1769 conferred […]
Tag Archives: Vaccine
No more annual flu shot? New target for universal influenza vaccine
Science Daily December 22, 2021 An international team of researchers (USA – University of Chicago, The Scripps Research Institute, La Jolla, CA, Icahn School of Medicine at Mount Sinai, New York, Fred Hutchinson Cancer Research Center, Seattle, WA, University of Washington, University of Maryland, Austria) has found a distinct class of broadly neutralizing antibodies (bnAbs) targeting a discrete membrane-proximal anchor epitope of the hemagglutinin (HA) stalk domain. The antibodies are broadly neutralizing across H1 viruses and can cross-react with pandemic-threat H2 and H5 viruses. Anchor epitope-targeting B cells are common in the human memory B cell (MBC) repertoire and were […]
Licensing Opportunity: Virus-Like Particle Technology for Universal Flu Vaccine
Global Biodefense July 13, 2021 The National Institutes of Health (NIH) has a Technology Transfer opportunity available for a virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes. The technology has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes, further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine…read […]